Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Front Immunol ; 9: 1346, 2018.
Article in English | MEDLINE | ID: mdl-29977236

ABSTRACT

Early immune responses to Mycobacterium tuberculosis (Mtb) invasion of the human lung play a decisive role in the outcome of infection, leading to either rapid clearance of the pathogen or stable infection. Despite their critical impact on health and disease, these early host-pathogen interactions at the primary site of infection are still poorly understood. In vitro studies cannot fully reflect the complexity of the lung architecture and its impact on host-pathogen interactions, while animal models have their own limitations. In this study, we have investigated the initial responses in human lung tissue explants to Mtb infection, focusing primarily on gene expression patterns in different tissue-resident cell types. As first cell types confronted with pathogens invading the lung, alveolar macrophages, and epithelial cells displayed rapid proinflammatory chemokine and cytokine responses to Mtb infection. Other tissue-resident innate cells like gamma/delta T cells, mucosal associated invariant T cells, and natural killer cells showed partially similar but weaker responses, with a high degree of variability across different donors. Finally, we investigated the responses of tissue-resident innate lymphoid cells to the inflammatory milieu induced by Mtb infection. Our infection model provides a unique approach toward host-pathogen interactions at the natural port of Mtb entry and site of its implantation, i.e., the human lung. Our data provide a first detailed insight into the early responses of different relevant pulmonary cells in the alveolar microenvironment to contact with Mtb. These results can form the basis for the identification of host markers that orchestrate early host defense and provide resistance or susceptibility to stable Mtb infection.

2.
J Infect Dis ; 217(10): 1667-1671, 2018 04 23.
Article in English | MEDLINE | ID: mdl-29471332

ABSTRACT

Persistence of Mycobacterium tuberculosis within human bone marrow stem cells has been identified as a potential bacterial niche during latent tuberculosis. Using a murine model of tuberculosis, we show here that bone marrow stem and progenitor cells containing M. tuberculosis propagated tuberculosis when transferred to naive mice, given that both transferred cells and recipient mice were unable to express inducible nitric oxide synthase, which mediates killing of intracellular bacteria via nitric oxide. Our findings suggest that bone marrow stem and progenitor cells containing M. tuberculosis propagate hallmarks of disease if nitric oxide-mediated killing of bacteria is defective.


Subject(s)
Hematopoietic Stem Cells/metabolism , Hematopoietic Stem Cells/microbiology , Mycobacterium tuberculosis/pathogenicity , Nitric Oxide Synthase Type II/metabolism , Stem Cells/metabolism , Stem Cells/microbiology , Tuberculosis/metabolism , Animals , Disease Models, Animal , Hematopoietic Stem Cell Transplantation/methods , Mice , Mice, Inbred C57BL , Nitric Oxide/metabolism , Tuberculosis/microbiology
3.
Proc Natl Acad Sci U S A ; 111(38): E4024-32, 2014 Sep 23.
Article in English | MEDLINE | ID: mdl-25201986

ABSTRACT

Lung granulomas develop upon Mycobacterium tuberculosis (Mtb) infection as a hallmark of human tuberculosis (TB). They are structured aggregates consisting mainly of Mtb-infected and -uninfected macrophages and Mtb-specific T cells. The production of NO by granuloma macrophages expressing nitric oxide synthase-2 (NOS2) via l-arginine and oxygen is a key protective mechanism against mycobacteria. Despite this protection, TB granulomas are often hypoxic, and bacterial killing via NOS2 in these conditions is likely suboptimal. Arginase-1 (Arg1) also metabolizes l-arginine but does not require oxygen as a substrate and has been shown to regulate NOS2 via substrate competition. However, in other infectious diseases in which granulomas occur, such as leishmaniasis and schistosomiasis, Arg1 plays additional roles such as T-cell regulation and tissue repair that are independent of NOS2 suppression. To address whether Arg1 could perform similar functions in hypoxic regions of TB granulomas, we used a TB murine granuloma model in which NOS2 is absent. Abrogation of Arg1 expression in macrophages in this setting resulted in exacerbated lung granuloma pathology and bacterial burden. Arg1 expression in hypoxic granuloma regions correlated with decreased T-cell proliferation, suggesting that Arg1 regulation of T-cell immunity is involved in disease control. Our data argue that Arg1 plays a central role in the control of TB when NOS2 is rendered ineffective by hypoxia.


Subject(s)
Arginase/metabolism , Granuloma/enzymology , Hypoxia/enzymology , Macrophages/enzymology , Mycobacterium tuberculosis , Tuberculosis, Pulmonary/enzymology , Animals , Arginase/genetics , Arginase/immunology , Arginine/genetics , Arginine/immunology , Arginine/metabolism , Cell Proliferation/genetics , Disease Models, Animal , Granuloma/genetics , Granuloma/immunology , Granuloma/pathology , Humans , Hypoxia/genetics , Hypoxia/immunology , Hypoxia/pathology , Lung/enzymology , Lung/immunology , Lung/pathology , Macrophages/immunology , Macrophages/pathology , Mice , Mice, Knockout , Nitric Oxide/genetics , Nitric Oxide/immunology , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/genetics , Nitric Oxide Synthase Type II/immunology , Nitric Oxide Synthase Type II/metabolism , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , T-Lymphocytes/pathology , Tuberculosis, Pulmonary/genetics , Tuberculosis, Pulmonary/immunology , Tuberculosis, Pulmonary/pathology
4.
Mycoses ; 56(5): 516-9, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23437896

ABSTRACT

The red algae Asparagopsis taxiformis collected from the Straits of Messina (Italy) were screened for antifungal activity against Aspergillus species. EUCAST methodology was applied and extracts showed antifungal activity against A. fumigatus, A. terreus and A. flavus. The lowest minimum inhibitory concentrations observed were <0.15 mg ml(-1) and the highest were >5 mg ml(-1) for Aspergillus spp. tested. Agar diffusion assays confirmed antifungal activity of A. taxiformis extracts in Aspergillus species.


Subject(s)
Antifungal Agents/pharmacology , Aspergillus/drug effects , Cell Extracts/pharmacology , Rhodophyta/chemistry , Antifungal Agents/isolation & purification , Cell Extracts/isolation & purification , Humans , Italy , Mediterranean Sea , Microbial Sensitivity Tests , Seawater/microbiology
5.
Vaccine ; 29(47): 8740-4, 2011 Nov 03.
Article in English | MEDLINE | ID: mdl-21871515

ABSTRACT

Bacille Calmette-Guérin (BCG) is the vaccine against tuberculosis (TB), but has varied efficacy in different geographical locations. Recombinant strategies to genetically modify the organism to enhance the quality of the immune response have aimed at improving BCG efficacy. Here we describe such a strategy using rBCGΔureC∷hly expressing defined latency-associated antigens and test this construct for long-term protection against an isolate of the Mycobacterium tuberculosis (Mtb) Beijing/W lineage. Expression of the antigens Rv2659c, Rv3407 and Rv1733c by rBCGΔureC∷hly improved long-term efficacy in both lung and spleen at day 200 post-infection after intradermal vaccination of mice. Our data support expression of Mtb latency associated antigens by rBCG to improve protection against Mtb.


Subject(s)
Antigens, Bacterial/immunology , BCG Vaccine/immunology , Mycobacterium tuberculosis/immunology , Animals , Antigens , Antigens, Bacterial/genetics , BCG Vaccine/administration & dosage , BCG Vaccine/genetics , Cation Transport Proteins , Colony Count, Microbial , Female , Injections, Intradermal , Lung/immunology , Lung/microbiology , Mice , Mice, Inbred BALB C , Mycobacterium tuberculosis/genetics , Spleen/immunology , Spleen/microbiology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology
6.
J Clin Invest ; 120(9): 3365-76, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20679732

ABSTRACT

The hallmark of human Mycobacterium tuberculosis infection is the presence of lung granulomas. Lung granulomas can have different phenotypes, with caseous necrosis and hypoxia present within these structures during active tuberculosis. Production of NO by the inducible host enzyme NOS2 is a key antimycobacterial defense mechanism that requires oxygen as a substrate; it is therefore likely to perform inefficiently in hypoxic regions of granulomas in which M. tuberculosis persists. Here we have used Nos2-/- mice to investigate host-protective mechanisms within hypoxic granulomas and identified a role for host serine proteases in hypoxic granulomas in determining outcome of disease. Nos2-/- mice reproduced human-like granulomas in the lung when infected with M. tuberculosis in the ear dermis. The granulomas were hypoxic and contained large amounts of the serine protease cathepsin G and clade B serine protease inhibitors (serpins). Extrinsic inhibition of serine protease activity in vivo resulted in distorted granuloma structure, extensive hypoxia, and increased bacterial growth in this model. These data suggest that serine protease activity acts as a protective mechanism within hypoxic regions of lung granulomas and present a potential new strategy for the treatment of tuberculosis.


Subject(s)
Granuloma/enzymology , Granuloma/microbiology , Lung/microbiology , Mycobacterium tuberculosis/growth & development , Mycobacterium tuberculosis/genetics , Serine Proteases/physiology , Tuberculosis, Pulmonary/enzymology , Tuberculosis, Pulmonary/pathology , Animals , Cathepsin G/metabolism , Hypoxia , Mice , Mice, Inbred C57BL , Mice, Knockout , Necrosis , Pulmonary Fibrosis/enzymology , Tuberculosis, Pulmonary/microbiology
7.
Int J Oncol ; 31(3): 567-76, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17671683

ABSTRACT

The prognosis of advanced pancreatic cancer is poor. Established chemotherapy shows only limited efficacy and significant side effects. We investigated how far a combination of trichostatin A (TSA) and gemcitabine synergizes to inhibit proliferation and promotion of apoptosis of pancreatic adenocarcinoma cells in vitro. The human pancreatic carcinoma cells YAPC, DANG and Panc-89 and primary human foreskin fibroblasts as non-malignant controls were cultured under standardized conditions and incubated with gemcitabine und TSA alone (10(-4) to 10(-8) M) or together (10(-6) to 10(-7) M). After 24-72 h the apoptotic rate was analyzed by flow cytometry (propidium iodide, FACS). DNA-synthesis was assessed using bromodeoxyuridine (BrdU) incorporation. Protein was separated for Western blotting against caspase-3 and -8, p21, bax and bcl-2. The combination of TSA und gemcitabine leads to better pro-apoptotic effects than the employment of single substances. Bcl-2, a mitochondrial protein, which protects against apoptosis, was not expressed. Bax, an apoptosis inducing protein, which destabilizes the mitochondrial membrane potential, was increasingly expressed. Combination of TSA and gemcitabine shows promise for treatment of pancreatic cancer in vivo.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Apoptosis/drug effects , Carcinoma/drug therapy , Cell Proliferation/drug effects , Deoxycytidine/analogs & derivatives , Hydroxamic Acids/administration & dosage , Pancreatic Neoplasms/drug therapy , Carcinoma/pathology , Caspase 3/biosynthesis , Caspase 8/biosynthesis , Cell Line, Tumor , Cell Separation , Deoxycytidine/administration & dosage , Flow Cytometry , Humans , Pancreatic Neoplasms/pathology , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Proto-Oncogene Proteins p21(ras)/biosynthesis , bcl-2-Associated X Protein/biosynthesis , Gemcitabine
8.
J Immunol ; 179(2): 1331-9, 2007 Jul 15.
Article in English | MEDLINE | ID: mdl-17617626

ABSTRACT

The role of CD8(+) T cells in human tuberculosis (TB) remains elusive. We analyzed the T cell repertoire and phenotype in 1) children with active TB (< or =4 years), 2) healthy latently Mycobacterium tuberculosis-infected children, and 3) noninfected age-matched (tuberculin skin test-negative) controls. Ex vivo phenotyping of T cell subpopulations by flow cytometry revealed a significant increase in the proportion of CD8(+)CD45RO(-)CD62L(-)CD28(-)CD27(-) effector T cells (T(EF)) in the peripheral blood of children with active TB (22.1 vs 9.5% in latently M. tuberculosis-infected children, vs 8.5% in tuberculin skin test-negative controls). Analyses of TCR variable beta-chains revealed markedly skewed repertoires in CD8(+) T(EF) and effector memory T cells. Expansions were restricted to single TCR variable beta-chains in individual donors indicating clonal growth. CDR3 spectratyping and DNA sequencing verified clonal expansion as the cause for CD8(+) effector T cell enrichment in individual TB patients. The most prominent enrichment of highly similar T(EF) clones (>70% of CD8(+) T(EF)) was found in two children with active severe TB. Therefore, clonal expansion of CD8(+) T(EF) occurs in childhood TB with potential impact on course and severity of disease.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Receptors, Antigen, T-Cell, alpha-beta/immunology , T-Lymphocyte Subsets/immunology , Tuberculosis/immunology , Amino Acid Sequence , Base Sequence , Child, Preschool , Clone Cells , Female , Flow Cytometry , Humans , Infant , Male , Molecular Sequence Data , Phenotype
9.
Antimicrob Agents Chemother ; 49(6): 2539-40, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15917567

ABSTRACT

This study used aleurioconidia as inoculum and compared the MICs of amphotericin B and voriconazole to those obtained for conidia of 31 Aspergillus terreus strains. For conidia and aleurioconidia, the MIC at which 90% of strains were inhibited was 2.5 microg/ml and 5 microg/ml with amphotericin B and 1 microg/ml and 2 microg/ml with voriconazole.


Subject(s)
Amphotericin B/pharmacology , Antifungal Agents/pharmacology , Aspergillus/growth & development , Pyrimidines/pharmacology , Triazoles/pharmacology , Aspergillus/drug effects , Humans , Hyphae/drug effects , Hyphae/growth & development , Microbial Sensitivity Tests , Voriconazole
10.
Oncol Rep ; 11(5): 943-50, 2004 May.
Article in English | MEDLINE | ID: mdl-15069530

ABSTRACT

Effective therapy for advanced hepatocellular carcinoma (HCC) is lacking. Conventional chemotherapy was judged to be ineffective. We previously demonstrated that the histone deacetylase inhibitor Trichostatin A (TSA) blocks growth of HCC cells in vitro. The anti-tumoral effect of a combination of more than 2 classes of drugs remains unexplored. Four hepatoma cell lines were incubated with increasing concentrations of Tamoxifen (TAM), 9-cis retinoic acid (CRA), the methioninaminopeptidase inhibitor TNP-470 and TSA as single agents and in combination. Anti-proliferative and pro-apoptotic effects were assessed using BrdU-incorporation, FACS analysis and immunocytochemistry. Central pro- and anti-apoptotic proteins were measured by semi-quantitative Western blotting and substrate assays. All single substances inhibited proliferation and induced apoptosis in HCC cells only at high concentrations. The combination of TAM/CRA/TNP/TSA multiplied the anti-tumoral effects, reaching up to 93% inhibition of proliferation and 63% induction of apoptosis after 24 h in Hep1B cells. Pro-apoptotic factors bax and caspase 3 were highly increased with quadruple therapy, while anti-apoptotic bcl-2 decreased to undetectable levels. Fibroblasts remained largely unaffected. While the single substances were not effective on hepatoma cells in tolerable doses, their combination significantly increases anti-tumoral efficacy. Combination therapy with biomodulators is a promising treatment option for HCC.


Subject(s)
Apoptosis/drug effects , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/pathology , Cell Division/drug effects , Hydroxamic Acids/pharmacology , Sesquiterpenes/pharmacology , Tamoxifen/pharmacology , Tretinoin/pharmacology , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Carcinoma, Hepatocellular/metabolism , Caspase 3 , Caspases/metabolism , Cell Cycle/drug effects , Cell Line, Tumor , Cyclin-Dependent Kinase Inhibitor p21 , Cyclins/metabolism , Cyclohexanes , DNA/biosynthesis , Drug Synergism , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Estrogen Antagonists/pharmacology , Estrogen Antagonists/therapeutic use , Humans , Hydroxamic Acids/therapeutic use , Immunologic Factors/pharmacology , Immunologic Factors/therapeutic use , Mice , O-(Chloroacetylcarbamoyl)fumagillol , Proto-Oncogene Proteins c-bcl-2/metabolism , Rats , Sesquiterpenes/therapeutic use , Tamoxifen/therapeutic use , Tretinoin/therapeutic use , bcl-2-Associated X Protein
SELECTION OF CITATIONS
SEARCH DETAIL
...